Bioavailability of BI 187004 and Metformin

Phase 1, randomised, open-label trial of BI 187004 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for BI 187004, Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for metformin and 2 more. Started May 2014; status: completed.